Activity Details
- Credit Type: CME
- Credit Amount: 2.00
- Cost: Free
- Release: Aug 1, 2008
- Expires: Aug 2, 2011
- Estimated Time to Complete:
2 Hour(s) - System Requirements:
Adobe Acrobat Reader
- Rate Activity:
Faculty
Annamaria Colao, MD, PhDProfessor of Endocrinology
Chief of the Neuroendocrine Unit University Federico II
Naples, Italy
John L. Haylor, bPharm, PhD, MRPSSheffield Kidney Institute Medical School
University of Sheffield
Sheffield, UK
Needs Statement
CML – Growth, a CME-accredited educational program, systematically identifies, evaluates, and places into clinical context the most important recent studies into the science and medicine of growth. It provides rapid access for busy specialists to a critical and clinically relevant review of the developments that will have most impact on their day-to-day practice and is designed to provide management options for clinicians to allow them to better diagnose and treat patients with growth disorders.Each issue of CML – Growth will present carefully constructed leading (review) articles, written by practicing specialists, and intended to equip readers with practical knowledge of the area under discussion. These articles are commissioned to support particular educational themes identified by the Editor-in-Chief, Editorial team and readers. This issue of CML – Growth presents two such leading articles.
Target Audience
This activity is designed to meet the educational needs of multidisciplinary clinicians and healthcare professionals involved in the care of patients with growth disorders.Objectives
After completing this activity learners will be able to discuss:1. The outcomes of surgical therapy and radiotherapy in acromegaly patients;
2. The therapeutic role of SSAs in the treatment of acromegaly;
3. The potential of GH antagonists and DA agonists in the treatment of acromegaly;
4. The effects of GH and IGF-1 resistance in uremia;
5. The outcomes of rhGH treatment on body growth, malnutrition, glomerular filtration rate and acute renal failure;
6. The side effects that can result from rhGH treatment.
Accreditation
CMEThis activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Kentucky College of Medicine and Remedica Medical Education. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.The University of Kentucky College of Medicine designates this educational activity for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.
Faculty Disclosure
Drs. Colao, Haylor and Kaun report no relevant financial relationships with commercials interests of healthcare products or services related to this activity.Disclosures from the Editorial Board can be found inside the PDF on page 3.

